Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel

NCT ID: NCT01591616

Last Updated: 2020-08-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-04-30
• Study Completion Date: 2012-04-30

Brief Summary

To establish Oraqix is safe when used on adolescent volunteers.

Detailed Description

This is a single-center, uncontrolled, open-label, single administration patient study. Male and female subjects aged 6 through 17 years of age in need of primary tooth extraction will be recruited from the Principal Investigator's database and may be supplemented by advertising. Subjects who withdraw from the study prematurely will be replaced.

Subjects will undergo an initial screening visit at which eligibility will be determined. After completion of informed consent/assent a physical examination, vitals, 12-lead ECG, and dental examination will be conducted. A medical history will be documented and a blood sample will be collected for analysis of biochemistry, hematology and as appropriate, serum pregnancy assessment for females.

Subjects will return to the office approximately 1 to 10 days after Visit 1 for Visit 2. At Visit 2, study treatment will be administered and PK blood samples will be collected for analysis, and monitored for safety parameters. Up to a total of five cartridges of Oraqix® will be administered to the oral cavity in the area of the tooth extraction, based on the body weight of the subject. No more than five cartridges will be dispensed, since this is the maximum dose for this agent. The final sample will be collected 4 hours after administration of study material. An abbreviated dental examination will be conducted, any adverse events (AEs) will be documented and the subject will be discharged from the clinic.

All subjects will be contacted by telephone approximately 24 hours after administration of study treatment. Study personnel will enquire about the occurrence of any AEs that have occurred since leaving the office. If appropriate, further follow-up of AEs will be arranged. In the absence of any ongoing AEs requiring follow up the subject will be considered to have completed the study at the completion of the telephone call.

Conditions

Periodontal Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Oraqix for tooth extraction

Group Type: OTHER

lidocaine and prilocaine

Intervention Type: DRUG

Appropriate dose of Oraqix based on weight will be given before tooth extraction

Interventions

lidocaine and prilocaine

Appropriate dose of Oraqix based on weight will be given before tooth extraction

Intervention Type: DRUG

Other Intervention Names

Oraqix periodontal gel

Eligibility Criteria

Inclusion Criteria

• 6 and 17 and eleven twelfths
• requires tooth extraction
• healthy having not taken any prescription or over the counter medications within 60 days of first visit
• must be a minimum of 15 kg

Exclusion Criteria

• anesthesia required for treatment other than study material
• given blood within 90 days of first visit
• pregnant
• allergic to local anesthetic
• documented history of glucose-6-phosphate dehydrogenase deficiency
• history of congenital idiopathic methemoglobinemia
• does not have a loose tooth easily extracted or who, in the opinion of the Investigator, is not suitable for tooth extraction using only topical anesthetic

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Dentsply International

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tegwyn Brickhouse, D.D.S PhD

Role: PRINCIPAL_INVESTIGATOR

Virginia Commonweath School of Dentistry

Locations

Virginia Commonweath School of Dentistry

Richmond, Virginia, United States

Countries

United States

Other Identifiers

TP73

Identifier Type: -

Identifier Source: org_study_id